Abstract: Objective To evaluate the clinical efficacy and safety of venlafaxine and duloxetine in the treatment of senile functional dyspepsia (FD). Methods Retrospective analysis the data of 96 cases senile functional dyspepsia which had treated in a hospital, from June 2015 to September 2016. All patients divided into venlafaxine group and duloxetine group. The venlafaxine treated with basic treatment+venlafaxine, while duloxetine treated with basic treatment+duloxetine, continuously for 12 weeks. Compared the PHQ-9 scores and adverse reaction, the the difference of curative effect between two groups analyzed by linear regression analysis. Results After treatment, the PHQ-9 scores of duloxetine group was significantly lower than venlafaxine group, and the difference was statistically significant (P <0.05). The non-depression rate of duloxetine group was higher than venlafaxine group, and the difference was statistically significant (P <0.05). Regression analysis showed that the efficacy of duloxetine group was about 2 times that of venlafaxine group, and had statistically significant (P <0.05). The effective rate of duloxetine group was significantly higher than venlafaxine group (P <0.05), and there was no serious adverse reaction in the two groups during treatment. Conclusion Compared with venlafaxine, duloxetine has better efficacy and less adverse effects in the treatment of FD.

Key words: functional dyspepsia, venlafaxine, duloxetine, clinical efficacy